A Phase I/II, Multicenter, Open-label Study of Oral FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression

Trial Profile

A Phase I/II, Multicenter, Open-label Study of Oral FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs FGF 401 (Primary) ; PDR 001
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2017 Results (n=67; data cut-off Nov 30, 2016) from the Phase I dose escalation part of the study presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 09 Mar 2017 Planned primary completion date changed from 15 May 2019 to 31 Dec 2018.
    • 08 Feb 2017 New drug PDR-001 has been added in the study. Due to this purpose, primary endpoints and treatment table also got updated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top